FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Geoffrey Gorse

Research Profile

Chemicals & Drugs

Living Beings

Procedures

Co-author Network

Publications

TOP 3
Geoffrey J Gorse; Terry L Poling; Cynthia B Strout; Ann R Falsey; John A Fling; Peter H Tsang
Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Geoffrey J Gorse; Christine Mhorag Hay; Spyros A Kalams; Brian D Livingston; Mark J Newman; Elizabeth Noonan; Farah L Cassis-Ghavami; Stephen C De Rosa; Allan deCamp; Jonathan D Fuchs
DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Geoffrey J Gorse; Gira B Patel; Joseph N Vitale; Theresa Z O'Connor
Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Geoffrey Gorse (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Geoffrey J Gorse; Terry L Poling; Cynthia B Strout; Ann R Falsey; John A Fling; Peter H Tsang
Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Vaccine 2013;31(19):2358-65.
2012: Geoffrey J Gorse; Christine Mhorag Hay; Spyros A Kalams; Brian D Livingston; Mark J Newman; Elizabeth Noonan; Farah L Cassis-Ghavami; Stephen C De Rosa; Allan deCamp; Jonathan D Fuchs
DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Clinical and vaccine immunology : CVI 2012;19(5):649-58.
2010: Geoffrey J Gorse; Gira B Patel; Joseph N Vitale; Theresa Z O'Connor
Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.
Clinical and vaccine immunology : CVI 2010;17(12):1875-80.
2009: Ann R Falsey; John J Treanor; Nadia Tornieporth; Jose Capellan; Geoffrey J Gorse
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
The Journal of infectious diseases 2009;200(2):172-80.
2009: Geoffrey J Gorse; Theresa Z O'Connor; Susan L Hall; Joseph N Vitale; Kristin L Nichol
Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.
The Journal of infectious diseases 2009;199(6):847-57.
2008: Ann R Falsey; Edward E Walsh; Jose Capellan; Stefan Gravenstein; Maria Zambon; Eddy Yau; Geoffrey J Gorse; Robert Edelman; Frederick G Hayden; Janet E McElhaney; Kathleen M Neuzil; Kristen L Nichol; Eric A F Simões; Peter F Wright; Valérie M-P Sales
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.
The Journal of infectious diseases 2008;198(9):1317-26.
2008: Geoffrey J Gorse; Lindsey R Baden; Margaret Wecker; Mark J Newman; Guido Ferrari; Kent J Weinhold; Brian D Livingston; Tonya L Villafana; Hongli Li; Elizabeth Noonan; Nina D Russell
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
Vaccine 2008;26(2):215-23.
2007: Geoffrey J Gorse; Wendy Keitel; Harry Keyserling; David N Taylor; Michael Lock; Katia Alves; Julie Kenner; Lynne Deans; Marc Gurwith
Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7".
Vaccine 2007;25(42):7285-7.
2006: Geoffrey J Gorse; Theresa Z O'Connor; Stephen L Young; Michael P Habib; Janet Wittes; Kathleen M Neuzil; Kristin L Nichol
Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination.
Chest 2006;130(4):1109-16.
2006: Geoffrey J Gorse; Wendy Keitel; Harry Keyserling; David N Taylor; Michael Lock; Katia Alves; Julie Kenner; Lynne Deans; Marc Gurwith
Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Vaccine 2006;24(33-34):5950-9.
2006: Geoffrey J Gorse; Ramona E Simionescu; Gira B Patel
Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
Clinical and vaccine immunology : CVI 2006;13(1):26-32.
2004: Clayton D Harro; Franklyn N Judson; Geoffrey J Gorse; Kenneth H Mayer; Jay R Kostman; Stephen J Brown; Beryl A Koblin; Michael Marmor; Bradford Bartholow; Vladimir Popovic
Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1385-92.
2004: Geoffrey J Gorse; Theresa Z O'Connor; Frances K Newman; Mahendra D Mandava; Paul M Mendelman; Janet Wittes; Peter Peduzzi
Immunity to influenza in older adults with chronic obstructive pulmonary disease.
The Journal of infectious diseases 2004;190(1):11-9.
2004: Peter F Wright; Jiri Mestecky; M Juliana McElrath; Michael C Keefer; Geoffrey J Gorse; Paul A Goepfert; Zina Moldoveanu; David Schwartz; Paul Spearman; Raphaelle El Habib; Michelle Donna Spring; Yuwei Zhu; Carol Smith; Jorge Flores; Kent J Weinhold
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
The Journal of infectious diseases 2004;189(7):1221-31.
2004: Geoffrey J Gorse; Gira B Patel; J Alan Arbuckle; Robert B Belshe
Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.
Vaccine 2004;22(3-4):383-97.
2003: Geoffrey J Gorse; Theresa Z O'Connor; Stephen L Young; Paul M Mendelman; Suzanne F Bradley; Kristin L Nichol; James H Strickland; Daniel M Paulson; Kathryn L Rice; Runi A Foster; Ashok M Fulambarker; John W Shigeoka; Ware G Kuschner; Richard P Goodman; Kathleen M Neuzil; Janet Wittes; Kathy D Boardman; Peter Peduzzi
Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study.
Vaccine 2003;21(17-18):2133-44.
2003: Kathleen M Neuzil; Theresa Z O'Connor; Geoffrey J Gorse; Kristin L Nichol
Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;36(2):169-74.
2002: Kalpana Gupta; Michael G Hudgens; Lawrence Corey; M Juliana McElrath; Kent J Weinhold; David C Montefiori; Geoffrey J Gorse; Sharon E Frey; Michael C Keefer; Thomas G Evans; Raphael Dolin; David H Schwartz; Clayton D Harro; Barney Graham; Paul Spearman; Mark MULLIGAN; Paul A Goepfert
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):254-61.
2001: Lisa A Jackson; G Austin; Robert T Chen; R Stout; Frank DeStefano; Geoffrey J Gorse; Frances K Newman; Onchee Yu; B G Weniger
Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.
Vaccine 2001;19(32):4703-9.
2001: Shewangizaw Worku; Geoffrey J Gorse; Robert B Belshe; Daniel F Hoft
Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.
The Journal of infectious diseases 2001;184(5):525-32.
2001: Geoffrey J Gorse; Gira B Patel; Robert B Belshe
HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
AIDS research and human retroviruses 2001;17(12):1175-89.
2001: Robert B Belshe; C Stevens; Geoffrey J Gorse; Susan Buchbinder; Kent J Weinhold; Haynes W Sheppard; Donald Stablein; S Self; James McNamara; Sharon Frey; J Flores; Jean-Louis Excler; M Klein; R E Habib; AM Duliege; Clayton D Harro; Lawrence Corey; Michael C Keefer; Mark MULLIGAN; P Wright; Connie Celum; Franklyn N Judson; K Mayer; David J McKirnan; Michael Marmor; George E Woody
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
The Journal of infectious diseases 2001;183(9):1343-52.
2001: Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2001: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; J A Arbuckle; Timothy M Doyle; Robert B Belshe
Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
Vaccine 2001;19(13-14):1806-19.
2000: M Juliana McElrath; Lawrence Corey; David Montefiori; Mark Wolff; David H Schwartz; Michael C Keefer; Robert B Belshe; Barney S Graham; T Matthews; P Wright; Geoffrey J Gorse; Raphael Dolin; Phillip W. Berman; D Francis; AM Duliege; Dani P Bolognesi; Donald Stablein; N Ketter; Patricia Fast
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 2000;16(9):907-19.
1999: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; Robert B Belshe
Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
Vaccine 1999;18(9-10):835-49.
1999: Peter F Wright; John S Lambert; Geoffrey J Gorse; RH Hsieh; M Juliana McElrath; Kent J Weinhold; Diane Wara; Edwin L Anderson; Michael C Keefer; S Jackson; LJ Wagner; D P Francis; Patricia Fast; James McNamara
Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women.
The Journal of infectious diseases 1999;180(4):1080-8.
1999: Thomas G Evans; Michael C Keefer; Kent J Weinhold; Mark Wolff; David Montefiori; Geoffrey J Gorse; Barney S Graham; M Juliana McElrath; Mary Lou Clements-Mann; Mark MULLIGAN; Patricia Fast; MC Walker; Jean-Louis Excler; AM Duliege; Jim Tartaglia
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
The Journal of infectious diseases 1999;180(2):290-8.
1999: Kristin L Nichol; Paul M Mendelman; Kenneth P Mallon; Lisa A Jackson; Geoffrey J Gorse; Robert B Belshe; W P Glezen; Janet Wittes
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;282(2):137-44.
1999: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; Phillip W. Berman; Robert B Belshe
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(10):921-30.
1999: Geoffrey J Gorse; Lawrence Corey; Gira B Patel; Mahendra D Mandava; RH Hsieh; TJ Matthews; MC Walker; M Juliana McElrath; Phillip W. Berman; M M Eibl; Robert B Belshe
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(2):115-32.
1998: Robert B Belshe; Geoffrey J Gorse; Mark MULLIGAN; Thomas G Evans; Michael C Keefer; Jean-Louis Excler; AM Duliege; Jim Tartaglia; W I Cox; James McNamara; K L Hwang; A Bradney; David Montefiori; Kent J Weinhold
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: Donald P Francis; TJ Gregory; M Juliana McElrath; Robert B Belshe; Geoffrey J Gorse; Sricharoen Migasena; Dwip Kitayaporn; P Pitisuttitham; T Matthews; David H Schwartz; Phillip W. Berman
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS research and human retroviruses 1998;14 Suppl 3():S325-31.
1998: Mary Lou Clements-Mann; Kent J Weinhold; TJ Matthews; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; RH Hsieh; Jiri Mestecky; Susan Zolla-Pazner; J Mascola; David H Schwartz; Robert Siliciano; Lawrence Corey; Peter F Wright; Robert B Belshe; Raphael Dolin; S Jackson; S Xu; Patricia Fast; MC Walker; Donald Stablein; Jean-Louis Excler; Jim Tartaglia; E Paoletti
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1998: Geoffrey J Gorse; M Juliana McElrath; TJ Matthews; RH Hsieh; Robert B Belshe; Lawrence Corey; Sharon E Frey; Donald J Kennedy; MC Walker; M M Eibl
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Vaccine 1998;16(5):493-506.
1998: Barney S Graham; M Juliana McElrath; Ruth I Connor; David H Schwartz; Geoffrey J Gorse; Michael C Keefer; Mark MULLIGAN; TJ Matthews; Steven Wolinsky; David C Montefiori; Sten Vermund; John S Lambert; Lawrence Corey; Robert B Belshe; Raphael Dolin; Peter F Wright; Bette T Korber; M C Wolff; Patricia Fast
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
The Journal of infectious diseases 1998;177(2):310-9.
1998: Lawrence Corey; M Juliana McElrath; Kent J Weinhold; T Matthews; Donald Stablein; B Graham; Michael C Keefer; David H Schwartz; Geoffrey J Gorse
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(2):301-9.
1997: Geoffrey J Gorse; E E Otto; C C Daughaday; Frances K Newman; Christopher S Eickhoff; Douglas C Powers; R H Lusk
Influenza virus vaccination of patients with chronic lung disease.
Chest 1997;112(5):1221-33.
1997: Michael C Keefer; Mark Wolff; Geoffrey J Gorse; Barney S Graham; Lawrence Corey; Mary Lou Clements-Mann; N Verani-Ketter; S Erb; C M Smith; Robert B Belshe; LJ Wagner; M Juliana McElrath; David H Schwartz; Patricia Fast
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1997;13(14):1163-77.
1997: Phillip W. Berman; A M Gray; T Wrin; JC Vennari; D J Eastman; G R Nakamura; D P Francis; Geoffrey J Gorse; David H Schwartz
Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
The Journal of infectious diseases 1997;176(2):384-97.
1997: SH Pincus; K G Messer; R Cole; R Ireland; T C VanCott; A Pinter; David H Schwartz; B S Graham; Geoffrey J Gorse
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(7):3511-20.
1996: Geoffrey J Gorse; E Y Yang; Robert B Belshe; Phillip W. Berman
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(6):769-73.
1996: Barney S Graham; Michael C Keefer; M Juliana McElrath; Geoffrey J Gorse; David H Schwartz; Kent J Weinhold; TJ Matthews; J R Esterlitz; F Sinangil; Patricia Fast
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
Annals of internal medicine 1996;125(4):270-9.
1996: Geoffrey J Gorse; Gira B Patel; F K Newman; Robert B Belshe; Phillip W. Berman; T J Gregory; TJ Matthews
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(4):378-86.
1996: John R Mascola; Stuart Snyder; O S Weislow; S M Belay; Robert B Belshe; David H Schwartz; M L Clements; Raphael Dolin; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; MC Walker; K F Wagner; John G McNeil; Francine E McCutchan; Donald S. Burke
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):340-8.
1996: Geoffrey J Gorse; Michael C Keefer; Robert B Belshe; TJ Matthews; B D Forrest; RH Hsieh; W C Koff; Carl Hanson; Raphael Dolin; Kent J Weinhold; Sharon E Frey; N Ketter; Patricia Fast
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):330-9.
1996: Geoffrey J Gorse; E E Otto; D C Powers; G W Chambers; C S Eickhoff; F K Newman
Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.
The Journal of infectious diseases 1996;173(2):285-90.
1995: Geoffrey J Gorse; Gira B Patel; F K Newman; Mahendra D Mandava; Robert B Belshe
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(13):1170-9.
1995: Geoffrey J Gorse; M J Campbell; E E Otto; D C Powers; G W Chambers; F K Newman
Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine.
The Journal of infectious diseases 1995;172(1):1-10.
1995: Geoffrey J Gorse; J H Rogers; J E Perry; F K Newman; Sharon E Frey; Gira B Patel; Robert B Belshe
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(2):209-14.
1994: Geoffrey J Gorse; David H Schwartz; B S Graham; TJ Matthews; D M Stablein; Sharon E Frey; Robert B Belshe; M L Clements; P F Wright; M Eibl
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Clinical and experimental immunology 1994;98(2):178-84.
1994: Barney S Graham; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; M Juliana McElrath; TJ Matthews; Peter F Wright; Robert B Belshe; M L Clements; Raphael Dolin
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1994;170(4):782-6.
1994: Robert B Belshe; Barney S Graham; Michael C Keefer; Geoffrey J Gorse; P Wright; Raphael Dolin; T Matthews; Kent J Weinhold; Dani P Bolognesi; R Sposto
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
JAMA : the journal of the American Medical Association 1994;272(6):475-80.
1994: Geoffrey J Gorse; Sharon E Frey; G Patel; F K Newman; Robert B Belshe
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1994;12(10):912-8.
1994: Phillip W. Berman; D J Eastman; D M Wilkes; G R Nakamura; T J Gregory; David H Schwartz; Geoffrey J Gorse; R Belshe; M L Clements; R A Byrn
Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
AIDS (London, England) 1994;8(5):591-601.
1994: Geoffrey J Gorse
Phase I/II trials of preventive HIV vaccine candidates. Dose and schedule: summary.
AIDS research and human retroviruses 1994;10 Suppl 2():S141-3.
1993: Robert B Belshe; M L Clements; Raphael Dolin; Barney S Graham; J McElrath; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; P Wright; L Corey
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
The Journal of infectious diseases 1993;168(6):1387-95.
1993: David H Schwartz; Geoffrey J Gorse; M L Clements; Robert B Belshe; Allen E Izu; AM Duliege; P Berman; T Twaddell; Donald Stablein; R Sposto
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
Lancet 1993;342(8863):69-73.
1993: Barney S Graham; TJ Matthews; Robert B Belshe; M L Clements; Raphael Dolin; Peter F Wright; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; Dani P Bolognesi
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1993;167(3):533-7.
1992: Geoffrey J Gorse; Sharon E Frey; F K Newman; Robert B Belshe
Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Journal of clinical microbiology 1992;30(10):2606-12.
1992: Kent J Weinhold; Jim Tartaglia; E Paoletti; B Graham; David H Schwartz; J McElrath; N Roberts; Geoffrey J Gorse
Specific activation strategies for amplification of low CTL signals.
AIDS research and human retroviruses 1992;8(8):1373.
1992: Barney S Graham; Robert B Belshe; M L Clements; Raphael Dolin; Lawrence Corey; Peter F Wright; Geoffrey J Gorse; K Midthun; Michael C Keefer; N J Roberts
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1992;166(2):244-52.
1992: Geoffrey J Gorse; Robert B Belshe; F K Newman; Sharon E Frey
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1992;10(6):383-8.
1991: R Dolin; Barney S Graham; S B Greenberg; Carol O Tacket; Robert B Belshe; K Midthun; M L Clements; Geoffrey J Gorse; B W Horgan; Robert L Atmar
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Annals of internal medicine 1991;114(2):119-27.